CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Cash Flow Y/Y Annual
Sage Therapeutics Inc   (NASDAQ: SAGE)
Other Ticker:  
 
 

SAGE's Net Cash Flow Growth by Quarter and Year

Sage Therapeutics Inc 's Net Cash Flow results by quarter and year

 



SAGE Net Cash Flow (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -19.99 -77.72 -37.13
3rd Quarter September - -0.27 27.30 -6.68
2nd Quarter June - 122.05 -85.08 27.84
1st Quarter March -35.80 103.16 43.86 -115.56
FY   -35.80 204.95 -91.64 -131.53

SAGEs Annual Net Cash Flow
Sage Therapeutics Inc 's Net Cash Flow in the fiscal year 2024 $ 10.15 millions
Sage Therapeutics Inc 's Net Cash Flow in the fiscal year 2023 $ -91.65 millions
Sage Therapeutics Inc 's Net Cash Flow in the fiscal year 2022 $ -131.53 millions
Sage Therapeutics Inc 's Net Cash Flow in the fiscal year 2021 $ -1,367.30 millions
Sage Therapeutics Inc 's Net Cash Flow in the fiscal year 2020 $ 1,533.73 millions




SAGE Net Cash Flow first quarter 2025 Y/Y Growth Comment
Sage Therapeutics Inc in the first quarter 2025 recorded net cash outflow of $ -35.80 millions.

According to the results reported in the first quarter 2025, Sage Therapeutics Inc achieved the best Net Cash Flow growth in Major Pharmaceutical Preparations industry. While Sage Therapeutics Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the first quarter 2025.


SAGE Net Cash Flow ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - 135.2 % - -
FY   - - - -

Financial Statements
Sage Therapeutics Inc 's first quarter 2025 Net Cash Flow $ -35.80 millions SAGE's Income Statement
Sage Therapeutics Inc 's first quarter 2024 Net Cash Flow $ 103.16 millions Quarterly SAGE's Income Statement


SAGE Net Cash Flow (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - 18.31 % - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Go to SAGE Cash flow Statement >> Back to SAGE Growth rate Comparisons >>


Net Cash Flow first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Sage Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SAGE's I. Quarter Q/Q Net Cash Flow Comment
Recent results of -35.80 millions by Sage Therapeutics Inc appear even less good if you take a look at net cash outflow -19.99 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Sage Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Sage Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SAGE's I. Quarter Q/Q Net Cash Flow Comment
I. Quarter 2025 net cash outflow of -35.80 millions by Sage Therapeutics Inc come out even less good if you take a look at net cash outflow -19.99 millions in the forth quarter.

Within Major Pharmaceutical Preparations industry Sage Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Sage Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Sage Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Net Cash Flow 12 Months Ending $ -128.81 $ 10.15 $ 71.36 $ -13.45 $ -32.34
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #


Cumulative Net Cash Flow growth Comment
Sage Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -129 millions in the Mar 31 2025 period.
The situation is detiriorating as the cumulative net cash outflow is inflating from $ 10.15 millions for the period from Dec 31 2024 to Mar 31 2024 and $ -91.645 millions for the twelve months ending in the quarter a year ago.

Sage Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
Sage Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -129 millions in the Mar 31 2025 period.
The business is getting worse as the cumulative net cash outflow is inflating from $ 10.15 millions in TTM ending quarter Dec 31 2024 and $ -91.645 millions for the twelve months ending in the quarter Mar 31 2024.

Sage Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
SAGE's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for SAGE's Competitors
Net Cash Flow Growth for Sage Therapeutics Inc 's Suppliers
Net Cash Flow Growth for SAGE's Customers

You may also want to know
SAGE's Annual Growth Rates SAGE's Profitability Ratios SAGE's Asset Turnover Ratio SAGE's Dividend Growth
SAGE's Roe SAGE's Valuation Ratios SAGE's Financial Strength Ratios SAGE's Dividend Payout Ratio
SAGE's Roa SAGE's Inventory Turnover Ratio SAGE's Growth Rates SAGE's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Mar 31 2025
Envista Holdings Corporation-3.53%$ -3.529 millions
Pluri Inc-6.84%$ -6.844 millions
Penumbra Inc-7.15%$ -7.151 millions
Regenxbio Inc -7.49%$ -7.489 millions
Sellas Life Sciences Group Inc -8.65%$ -8.650 millions
Viatris Inc -9.42%$ -9.417 millions
Nautilus Biotechnology Inc -11.69%$ -11.687 millions
Arcus Biosciences Inc -27.59%$ -27.586 millions
Staar Surgical Co-29.35%$ -29.354 millions
Ironwood Pharmaceuticals inc -32.21%$ -32.206 millions
Ani Pharmaceuticals Inc-33.90%$ -33.895 millions
Acurx Pharmaceuticals inc -35.22%$ -35.222 millions
Cryoport inc -37.53%$ -37.534 millions
Iqvia Holdings Inc -44.12%$ -44.118 millions
Amphastar Pharmaceuticals Inc -45.17%$ -45.168 millions
Seer Inc -46.61%$ -46.609 millions
Serina Therapeutics Inc -47.67%$ -47.669 millions
Humacyte Inc -48.91%$ -48.912 millions
Cytomx Therapeutics Inc -49.76%$ -49.758 millions
Rxsight Inc -50.80%$ -50.797 millions
Charles River Laboratories International inc -51.61%$ -51.609 millions
Blueprint Medicines Corporation-53.52%$ -53.519 millions
Royalty Pharma Plc-56.64%$ -56.640 millions
Adaptive Biotechnologies Corporation-59.03%$ -59.032 millions
Pliant Therapeutics Inc -59.37%$ -59.368 millions
Livanova Plc-60.64%$ -60.644 millions
Catalyst Pharmaceuticals Inc -63.48%$ -63.477 millions
Qt Imaging Holdings Inc -66.72%$ -66.724 millions
Creative Medical Technology Holdings Inc -68.19%$ -68.190 millions
Dyne Therapeutics Inc -75.46%$ -75.465 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com